• Explore /
  • Poster
  • / SOGUG-vexillum: Phase II non-randomized clinical trial of nivolumab/ipilimumab maintenance following first-line chemotherapy in unresectable locally advanced or metastatic urothelial cancer.

SOGUG-vexillum: Phase II non-randomized clinical trial of nivolumab/ipilimumab maintenance following first-line chemotherapy in unresectable locally advanced or metastatic urothelial cancer.

Abstract Poster

Authors

null

Guillermo de Velasco

Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid, Spain

Guillermo de Velasco , Carlos Alvarez-Fernandez , Francisco Jose Alvarez Marquez , Oscar Reig Torras , Juan Antonio Virizuela , Urbano Anido , Aitor Azkarate , Pablo Gajate , Iciar Garcia Carbonero , Aina Iranzo Sabater , Rebeca Lozano , Eduardo Pujol

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Kidney and Bladder

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Urothelial Cancer - Advanced/Metastatic Disease

Clinical Trial Registration Number

EudraCT 2021-005364-22

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr TPS4606)

DOI

10.1200/JCO.2023.41.16_suppl.TPS4606

Abstract #

TPS4606

Poster Bd #

95b

Abstract Disclosures

Similar Posters

First Author: Rohit K. Jain

First Author: Begoña Pérez-Valderrama

First Author: Srikala S. Sridhar

First Author: Yohann Loriot